Durham-based Scioderm, which sold to Amicus Therapeutics in a deal potentially worth $947 million in August, has won a $400,0000 grant from the U.S. Food and Drug Administration. The company is developing a treatment for a rare skin disease that usually affects children.
The grant is part of 17 projects developing treatments for rare diseases which in total received grants of $19 million.
Scioderm is developing Zorblisa to treat the rare skin disease Epidermolysis Bullosa, which generally afflicts children and infants.
Dr. Gayatri Rao, director of the FDA’s orphan drug program said the FDA is in a unique position to help beat rare diseases by offering product development incentives. He noted that this years grants support “Much needed research in 17 different rare diseases,” most with no available treatment options.
